Federal regulators on Wednesday approved Eli Lilly's new weight-loss pill, a second daily oral medication to treat obesity ...
FY25 profit surge, discounted valuation, and ReSPECT Phase III Rezzayo catalyst in Q2 2026. Click for this CRMD update.
The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...
A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose ...
Zongertinib has shown “robust activity” in the treatment of advanced, treatment-naïve, HER2-mutant non-small cell lung cancer.
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results